Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials

BACKGROUND: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 is largely unknown. METHODS: We identified patients with uncommon EGFR-mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Eide, Inger Johanne Zwicky, Stensgaard, Simone, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Sørensen, Boe Sandahl, Brustugun, Odd Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271433/
https://www.ncbi.nlm.nih.gov/pubmed/35832438
http://dx.doi.org/10.21037/tlcr-21-995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271433/
https://www.ncbi.nlm.nih.gov/pubmed/35832438
http://dx.doi.org/10.21037/tlcr-21-995

Ejemplares similares